SCHEMBL3632373

SCHEMBL3632373

CCCCCCCCCCCCCCCCOCCCCCCCCCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 1/20 0.48
MCHR1 Q99705 1/20 0.47
RECQL P46063 2/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
EPHX2 P34913 1/20 0.46
BLM P54132 1/20 0.46
ALDH1A1 P00352 2/20 0.44
CA1 P00915 9/20 0.43
CA2 P00918 9/20 0.43
CA9 Q16790 8/20 0.43
CA12 O43570 3/20 0.43
CA7 P43166 3/20 0.43
CA14 Q9ULX7 3/20 0.43
CA3 P07451 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20548023 1.00 PLA2G2C (0.48) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL20129041 1.00 PLA2G2C (0.48) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL10590732 1.00 PLA2G2C (0.48) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL18473044 0.98 PLA2G2C (0.47) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL20129020 0.98 PLA2G2C (0.46) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL13672853 0.97 PLA2G2C (0.45) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL26813058 0.97 PLA2G2C (0.45) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL18494142 0.95 PLA2G2C (0.44) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL17309273 0.95 PLA2G2C (0.47) PLA2G2CMCHR1RECQLGLAHPGD
SCHEMBL6652024 0.95 PLA2G2C (0.47) PLA2G2CMCHR1RECQLGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687483-B2 Derivatives of branch-chain lipophilic molecular and uses thereof D-PHARM LTD. (IL) 2010-03-30 US disclosed
EP-1305322-B1 DERIVATIVES OF BRANCHED-CHAIN LIPOPHILIC MOLECULES AND USES THEREOF DPHARM LTD (IL) 2010-01-13 EP disclosed
US-20070135381-A1 Derivatives of branch-chain lipophilic molecular and uses thereof D-PHARM LTD. (IL) 2007-06-14 US disclosed
US-7186703-B2 Derivatives of branched-chain lipophilic molecules and uses thereof D-PHARM LTD. (IL) 2007-03-06 US disclosed
CN-1633440-A Branched-chain lipophilic molecule derivatives and uses thereof DPHARM LTD (IL) 2005-06-29 CN disclosed
US-20030186897-A1 Derivatives of branched-chain lipophilic molecules and uses thereof D-PHARM, LTD. (IL) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135381-A1 Derivatives of branch-chain lipophilic molecular and uses thereof PLIN3, GLS, LIPG PLA2G2C 157/4885MCHR1 4729/4885RECQL 4406/4885
US-20030186897-A1 Derivatives of branched-chain lipophilic molecules and uses thereof PLIN3, PLIN5, SLC27A1 PLA2G2C 542/4885MCHR1 4636/4885RECQL 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.